title: Pharmacogenomics of endocrine therapy in breast cancer.
abstract: The most important modality of treatment in the two-thirds of patients with an estrogen receptor (ER)-positive early breast cancer is endocrine therapy. In postmenopausal women, options include the selective ER modulators (SERMs), tamoxifen and raloxifene, and the 'third-generation' aromatase inhibitors (AIs), anastrozole, exemestane and letrozole. Under the auspices of the National Institutes of Health Global Alliance for Pharmacogenomics, Japan, the Mayo Clinic Pharmacogenomics Research Network Center and the RIKEN Center for Genomic Medicine have worked collaboratively to perform genome-wide association studies (GWAS) in women treated with both SERMs and AIs. On the basis of the results of the GWAS, scientists at the Mayo Clinic have proceeded with functional genomic laboratory studies. As will be seen in this review, this has led to new knowledge relating to endocrine biology that has provided a clear focus for further research to move toward truly personalized medicine for women with breast cancer.
authors: Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA. Ingle.james@mayo.edu
authors: James N
authors: JN
authors: Ingle
mesh_terms: D000077384:Anastrozole; D000730:Androstadienes / Q000627:therapeutic use; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D047072:Aromatase Inhibitors / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics; D017024:Chemotherapy, Adjuvant; D005260:Female; D055106:Genome-Wide Association Study; D006801:Humans; D007564:Japan; D000077289:Letrozole; D009142:Musculoskeletal Physiological Phenomena / Q000187:drug effects; D009570:Nitriles / Q000627:therapeutic use; D010597:Pharmacogenetics / Q000379:methods*; D010641:Phenotype; D017698:Postmenopause; D020849:Raloxifene Hydrochloride / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D020845:Selective Estrogen Receptor Modulators / Q000627:therapeutic use*; D013629:Tamoxifen / Q000627:therapeutic use; D014230:Triazoles / Q000627:therapeutic use
chemical_list: D000730:Androstadienes; D018931:Antineoplastic Agents, Hormonal; D047072:Aromatase Inhibitors; D009570:Nitriles; D020845:Selective Estrogen Receptor Modulators; D014230:Triazoles; D013629:Tamoxifen; D000077384:Anastrozole; D020849:Raloxifene Hydrochloride; D000077289:Letrozole; C056516:exemestane
references: Osteoporos Int. 2006 Dec;17(12):1726-33
references: 16983459
references: J Clin Oncol. 2006 Nov 20;24(33):5305-12
references: 17114665
references: Breast Cancer Res Treat. 2008 Sep;111(2):365-72
references: 17922185
references: J Clin Oncol. 2010 Nov 1;28(31):4674-82
references: 20876420
references: Cancer Res. 2010 Jan 1;70(1):319-28
references: 20048079
references: Best Pract Res Clin Endocrinol Metab. 2008 Oct;22(5):723-35
references: 19028354
references: J Clin Oncol. 2010 Jun 20;28(18):3090-5
references: 20458026
references: J Clin Oncol. 2010 Aug 10;28(23):3784-96
references: 20625130
references: N Engl J Med. 2009 Aug 20;361(8):818-20
references: 19671654
references: J Clin Oncol. 2008 Feb 1;26(4):556-62
references: 18180462
references: J Clin Endocrinol Metab. 2008 Mar;93(3):861-8
references: 18160467
references: Cancer Res. 2010 Apr 15;70(8):3278-86
references: 20354183
references: Genome Res. 2010 Nov;20(11):1482-92
references: 20923822
references: Nat Genet. 2012 Apr 15;44(5):491-501
references: 22504420
references: N Engl J Med. 2009 Aug 27;361(9):888-98
references: 19710487
references: JAMA. 2006 Jun 21;295(23):2727-41
references: 16754727
references: J Clin Oncol. 2007 May 20;25(15):2127-32
references: 17513820
references: Endocr Rev. 1994 Jun;15(3):342-55
references: 8076586
references: Cancer Res. 2008 Sep 1;68(17):7050-8
references: 18757419
references: Nature. 2010 Oct 28;467(7319):1061-73
references: 20981092
references: J Immunol. 2005 May 1;174(9):5789-95
references: 15843582
references: Arch Intern Med. 2006 Nov 13;166(20):2260-5
references: 17101945
references: J Clin Oncol. 2010 Jan 20;28(3):509-18
references: 19949017
references: Cancer Discov. 2013 Jul;3(7):812-25
references: 23764426
references: J Clin Oncol. 2010 Nov 1;28(31):4665-6
references: 20876427
references: J Steroid Biochem Mol Biol. 2003 Sep;86(3-5):219-24
references: 14623514
references: J Natl Cancer Inst. 1998 Sep 16;90(18):1371-88
references: 9747868
references: Cancer Prev Res (Phila). 2010 Jun;3(6):696-706
references: 20404000
references: J Steroid Biochem Mol Biol. 2005 May;95(1-5):151-4
references: 15970439
references: J Clin Oncol. 2013 Apr 10;31(11):1398-404
references: 23358971
references: Clin Cancer Res. 2011 Nov 1;17(21):6944-51
references: 21880792
references: J Clin Oncol. 2007 Sep 1;25(25):3877-83
references: 17761973
references: Lancet. 2002 May 18;359(9319):1761-7
references: 12049882
references: Steroids. 2011 Jul;76(8):765-7
references: 21382394
references: Mol Endocrinol. 2013 Apr;27(4):657-70
references: 23518928
references: Lancet. 2011 Aug 27;378(9793):771-84
references: 21802721
references: CA Cancer J Clin. 2013 Jan;63(1):11-30
references: 23335087
references: Lancet. 2003 Jan 25;361(9354):296-300
references: 12559863
references: Breast Cancer Res. 2012 Mar 09;14(2):R41
references: 22405131
references: Cancer Res. 2005 Dec 1;65(23):11071-82
references: 16322257